Evidence map›Paper›PMID 32698268›Full record

ArticleInternational journal of surgery case reports2020

A Case of Pathological Complete Response Following FOLFIRINOX Therapy for Pancreatic Adenocarcinoma with Synchronous Distant Lymph Node Metastases.

Masanori Tsujie, Soichi Fumita, Tomoko Wakasa, Shigeto Mizuno, Hajime Ishikawa, Kotaro Kitani, Shumpei Satoi, Kaoru Okada, Keisuke Inoue, Shuichi Fukuda and 8 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in International journal of surgery case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Masanori TsujieDepartment of Gastroenterological Surgery, Kindai University Nara Hospital, Japan; Department of Surgery, Osaka Rosai Hospital, Japan. Electronic address: tsujie@osakah.johas.go.jp.
Soichi FumitaDepartment of Medical Oncology, Kindai University Nara Hospital, Japan. Electronic address: med170470@med.kindai.ac.jp.
Tomoko WakasaDepartment of Pathology, Kindai University Nara Hospital, Japan. Electronic address: wakasa@med.kindai.ac.jp.
Shigeto MizunoDepartment of Endoscopic Diagnosis and Treatment, Kindai University Nara Hospital, Japan. Electronic address: s-mizuno@med.kindai.ac.jp.
Hajime IshikawaDepartment of Gastroenterological Surgery, Kindai University Nara Hospital, Japan. Electronic address: h-ishikawa@med.kindai.ac.jp.
Kotaro KitaniDepartment of Gastroenterological Surgery, Kindai University Nara Hospital, Japan. Electronic address: kitani@med.kindai.ac.jp.
Shumpei SatoiDepartment of Gastroenterological Surgery, Kindai University Nara Hospital, Japan. Electronic address: s-satoi@med.kindai.ac.jp.
Kaoru OkadaDepartment of Gastroenterological Surgery, Kindai University Nara Hospital, Japan. Electronic address: kao1002oka@gmail.com.
Keisuke InoueDepartment of Gastroenterological Surgery, Kindai University Nara Hospital, Japan. Electronic address: inoue-ke@herb.ocn.ne.jp.
Shuichi FukudaDepartment of Gastroenterological Surgery, Kindai University Nara Hospital, Japan. Electronic address: s.fukuda@med.kindai.ac.jp.
Hironobu ManabeDepartment of Gastroenterological Surgery, Kindai University Nara Hospital, Japan. Electronic address: hiro-manabe@med.kindai.ac.jp.
Noriko IchimuraDepartment of Nursing, Kindai University Nara Hospital, Japan. Electronic address: n-ichimura@med.kindai.ac.jp.
Shinya UedaDepartment of Medical Oncology, Kindai University Nara Hospital, Japan. Electronic address: s-ueda@med.kindai.ac.jp.
Takao TamuraDepartment of Medical Oncology, Kindai University Nara Hospital, Japan. Electronic address: ttamura@med.kindai.ac.jp.
Toshihiko KawasakiDepartment of Gastroenterology, Kindai University Nara Hospital, Japan. Electronic address: toshi1958@med.kindai.ac.jp.
Masao YukawaDepartment of Gastroenterological Surgery, Kindai University Nara Hospital, Japan. Electronic address: myukawa@med.kindai.ac.jp.
Yoshio OhtaDepartment of Pathology, Kindai University Nara Hospital, Japan. Electronic address: naraohta@med.kindai.ac.jp.
Masatoshi InoueDepartment of Gastroenterological Surgery, Kindai University Nara Hospital, Japan. Electronic address: minoue@med.kindai.ac.jp.
Kindai University Hospital · JPKindai University · JPNara Medical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe report a case of conversion surgery for pancreatic ductal adenocarcinoma (PDAC) with synchronous distant metastases showing pathological complete response (pCR) after FOLFIRINOX therapy. PRESENTATION OF CASE: A 46-year-old woman with obstructive jaundice was referred to our hospital. A CT scan revealed a hypo-vascular mass in the head of the pancreas with multiple para-aortic lymph nodes and a Virchow's node swollen. The serum CA 19-9 level was 71795.1 U/mL. The result of tumor biopsy from the biliary stenotic site was concordant with adenocarcinoma. She was diagnosed with PDAC with distant metastases. After 10 courses of FOLFIRINOX followed by 4 courses of FOLFIRI, a CT scan showed that distant lymph node swellings disappeared, and CA19-9 level became almost normal. She underwent pancreaticoduodenectomy with dissection of para-aortic lymph nodes 8 months after the initiation of chemotherapy. Pathologically, no evidence of residual adenocarcinoma was observed in neither pancreas nor lymph nodes. Adjuvant chemotherapy using S-1 was administered for 6 months, and no recurrence has been observed 4 years after surgery. BRCA1/2 mutations were not detected in patient's DNA. DISCUSSION: With the induction of intensive chemotherapies such as FOLFIRINOX, an increasing number of patients with synchronous distant metastases could become suitable candidates for surgery of the primary lesion because of the potential complete response of metastatic lesions.

conclusionThis case presented a rare occurrence of pCR in a patient with unresectable PDAC with distant metastases who received FOLFIRINOX. The feasibility and benefits of conversion surgery in such patients must be investigated in future trials.

Indexed as

BRCA1/2 mutationCase reportConversion surgeryDistant metastasisFOLFIRINOXUnresectable pancreatic cancer

Identifiers

PMID32698268
PMCPMC7322239
OpenAlexW3034936166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.